Form 4: Enveric Biosciences Director Receives Restricted Stock

Enveric Biosciences Director Sheila DeWitt was granted 7,633 restricted shares, with her total beneficial ownership adjusted for recent reverse stock splits.

Summary

• Sheila DeWitt, a Director of Enveric Biosciences, Inc. (ENVB), acquired 7,633 shares of common stock on December 23, 2025.
• The acquisition was a grant of restricted stock under the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended, with a transaction price of $0 per share.
• Following this transaction, Sheila DeWitt beneficially owns 7,788 shares of common stock.
• The reported share amounts have been adjusted to reflect two reverse stock splits: a 1-for-15 split on January 29, 2025, and a 1-for-12 split on October 28, 2025.

Sentiment

Score: 6

Explanation: The grant of restricted stock to a director is a positive for aligning interests. However, the context of two significant reverse stock splits within the year suggests underlying challenges with the company's stock performance, tempering overall sentiment.

Positives

• The grant of restricted stock to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The shares were granted under an established Long-Term Incentive Plan, indicating a structured approach to executive compensation.

Negatives

• The company underwent two significant reverse stock splits (1-for-15 and 1-for-12) within 2025, which often indicates a struggling stock price or efforts to maintain listing compliance, generally viewed negatively by the market.

Future Outlook

The restricted shares granted to Sheila DeWitt are subject to vesting in accordance with the terms and conditions of the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan and her restricted stock award agreement.

Industry Context

Form 4 filings are standard disclosures for insider transactions, providing transparency into changes in beneficial ownership by company directors and officers. Reverse stock splits, as seen here, are common in the biotechnology sector for companies seeking to maintain compliance with exchange listing requirements or to make their stock more attractive to institutional investors, often following periods of significant share price decline.

Corporate Governance

Related Party Transactions

• The grant of 7,633 restricted shares to Sheila DeWitt, a Director of Enveric Biosciences, Inc., constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Increased director ownership can signal confidence and better alignment of interests, but the reverse stock splits may raise concerns about past stock performance.
• Employees: The use of a long-term incentive plan for directors suggests a structured approach to compensation that may extend to other key personnel.

Next Steps

• Vesting of the granted restricted shares will occur according to the terms of the 2020 Long-Term Incentive Plan and the award agreement.

Key Dates

Keywords

Enveric Biosciences, ENVB, Form 4, Insider Transaction, Restricted Stock, Stock Grant, Reverse Stock Split, Director Compensation, Beneficial Ownership